Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen-Reference-Cited by-同舟云学术

Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen

Published:2020-12-14 Issue:4 Volume:15 Page:957-967
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Helland Thomas¹²^ORCID,Naume Bjørn³⁴,Hustad Steinar⁵,Bifulco Ersilia⁵,Kvaløy Jan Terje⁶⁷,Sætersdal Anna Barbro³,Synnestvedt Marit³,Lende Tone Hoel⁸,Gilje Bjørnar⁹,Mjaaland Ingvil⁹,Weyde Kjetil¹⁰,Blix Egil Støre¹¹¹²,Wiedswang Gro¹³,Borgen Elin¹⁴,Hertz Daniel Louis¹⁵,Janssen Emiel Adrianus Maria¹⁶¹⁷,Mellgren Gunnar¹²,Søiland Håvard²⁹^ORCID

Affiliation:

1. Hormone Laboratory Department of Medical Biochemistry and Pharmacology Haukeland University Hospital Bergen Norway

2. Department of Clinical Science University of Bergen Norway

3. Department of Oncology Division of Cancer Medicine Oslo University Hospital Norway

4. Institute of Clinical Medicine Faculty of Medicine University of Oslo Norway

5. Core Facility for Metabolomics Department of Clinical Science University of Bergen Norway

6. Department of Mathematics and Physics University of Stavanger Norway

7. Department of Research Stavanger University Hospital Norway

8. Department of Surgery Section for Breast and Endocrine Surgery Stavanger University Hospital Norway

9. Department of Oncology and Radiotherapy Stavanger University Hospital Norway

10. Department of Oncology Sykehuset Innlandet Gjøvik Norway

11. Immunology Research Group Institute of Medical Biology University of Tromsø Norway

12. Department of Oncology University Hospital of North Norway Tromsø Norway

13. Department of GI‐Surgery Oslo University Hospital Norway

14. Department of Pathology Oslo University Hospital Norway

15. Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor MI USA

16. Department of Pathology Stavanger University Hospital Norway

17. Department of Bioscience and Environmental Engineering University of Stavanger Norway

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12865

Reference35 articles.

1. NBCG(2017)National action plan with guidelines for diagnosis treatment and follow up of breast cancer patients p.81–84.Norwegian Directory of Health.www.helsedirektoratet.no.

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

3. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

4. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

5. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort;Clinical Pharmacology & Therapeutics;2024-03-18

2. Impact of CYP2D6, CYP2C9/19, CYP3A4, UGT, and SULT Variability on Tamoxifen Metabolism in Breast Cancer Treatment;Journal of Current Oncology;2024-02-27

3. Breast Cancer Image Classification based on Adaptive Interpolation Approach Using Clinical Dataset;Scalable Computing: Practice and Experience;2024-02-24

4. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review;BMC Cancer;2023-07-04

5. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer;Breast Cancer Research and Treatment;2023-04-17